• Neuralstem Inc., of Rockville, Md., said it started dosing in the second cohort of patients in its Phase Ib trial testing NSI-189 in major depressive disorder. The study is enrolling 24 patients, and the Phase Ib portion is expected to take about six months to complete. NSI-189 is a small molecule designed to stimulate new neuron growth in the hippocampus.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter